LXEO Form 4: Chief Development Officer sells 382 shares amid RSU vesting

Rhea-AI Filing Summary

Insider sale to cover taxes at Lexeo Therapeutics (LXEO) Reporting person Tai Sandi, Chief Development Officer, reported a sale of 382 shares of common stock on 08/18/2025 at $4.668 per share. The filing states the sale was a "sale to cover" related to the release of restricted stock units (RSUs). After the transaction, the reporting person beneficially owned 58,860 shares, which the filer notes include 49,138 RSUs. The Form 4 was signed by an attorney-in-fact on 08/20/2025. No derivative transactions or other securities changes are reported in this filing.

Insights

Corporate Governance Expert

TL;DR: Routine tax-motivated sale of a small number of shares from RSU release; not a material change to ownership.

The sale of 382 shares at $4.668 to satisfy tax obligations on RSU vesting is a common, non-dispositive insider transaction. With 58,860 shares beneficially owned post-transaction and 49,138 RSUs included in that total, the transaction appears administrative rather than strategic. There is no indication of derivative activity or additional disposals. For investors assessing governance signals, this filing aligns with typical executive compensation tax-withholding settlements and does not, by itself, indicate a change in company outlook or insider confidence.

Securities Analyst

TL;DR: Small-volume insider sale tied to RSU tax withholding; unlikely to affect float or market perception materially.

The transaction volume (382 shares) and price ($4.668) are modest relative to typical market capitalization for a public company and are explicitly described as a sale to cover taxes. The disclosure clarifies that a significant portion of the reporting person’s stake consists of unexercised RSUs (49,138), which remain subject to vesting or restriction terms. No cash-for-stock buybacks, option exercises, or other compensation-related mechanics beyond the tax sale are disclosed. Impact on investor valuation metrics is negligible based on this filing alone.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

See Tai Sandi

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2025		S(1)		382	D	$4.668	58,860(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").

2. Includes 49,138 RSUs.

	/s/ Youjin Choi, Attorney-in-Fact	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Tai Sandi report on Form 4 for Lexeo Therapeutics (LXEO)?

The filer reported a sale of 382 shares on 08/18/2025 at $4.668 per share to cover tax obligations from RSU vesting.

How many shares does the reporting person own after the transaction?

The reporting person beneficially owned 58,860 shares following the reported transaction, which includes 49,138 RSUs.

Was the transaction part of an option exercise or derivative transaction?

No. The Form 4 discloses a non-derivative sale to cover taxes on RSUs and does not report any derivative transactions.

When was the Form 4 signed and who signed it?

The form was signed by Youjin Choi, Attorney-in-Fact on 08/20/2025.

Does the filing indicate any change in officer status or relationship to the company?

The filing lists the reporter as an officer (Chief Development Officer) and does not indicate any change in that relationship.